Hon ANDREW LITTLE: The Pfizer antiviral is expected to be delivered to New Zealand in April, once approved by Medsafe. These medicines will be an important asset as we continue to prepare for winter in 2022 and will work alongside our wider suite of COVID-19 medicines already secured by Pharmac, which includes baricitinib, remdesivir, tocilizumab, and ronapreve. We've made sure Pharmac can continue to secure early access to new and promising COVID medicines as soon as possible, with $175 million allocated for medicines and supply chain costs and another $300 million available for purchasing more COVID-19 therapeutics.